243 related articles for article (PubMed ID: 16269215)
1. The KRAS oncogene: past, present, and future.
Kranenburg O
Biochim Biophys Acta; 2005 Nov; 1756(2):81-2. PubMed ID: 16269215
[No Abstract] [Full Text] [Related]
2. Screening of mutations in the ras family of oncogenes by polymerase chain reaction-based ligase chain reaction.
Martínez A; Lehman TA; Modali R; Mulshine JL
Methods Mol Med; 2003; 74():187-200. PubMed ID: 12415694
[No Abstract] [Full Text] [Related]
3. Oncogenic activating mutations are associated with local copy gain.
Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
[TBL] [Abstract][Full Text] [Related]
4. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.
Tie J; Lipton L; Desai J; Gibbs P; Jorissen RN; Christie M; Drummond KJ; Thomson BN; Usatoff V; Evans PM; Pick AW; Knight S; Carne PW; Berry R; Polglase A; McMurrick P; Zhao Q; Busam D; Strausberg RL; Domingo E; Tomlinson IP; Midgley R; Kerr D; Sieber OM
Clin Cancer Res; 2011 Mar; 17(5):1122-30. PubMed ID: 21239505
[TBL] [Abstract][Full Text] [Related]
5. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras.
Volm M; Mattern J
Anticancer Res; 1993; 13(6A):2021-5. PubMed ID: 8297109
[TBL] [Abstract][Full Text] [Related]
6. How can we identify new biomarkers for patients with for lung metastasectomy in colorectal cancer.
Renaud S; Falcoz PE
Future Oncol; 2015; 11(15):2109-11. PubMed ID: 26235176
[No Abstract] [Full Text] [Related]
7. Methods for isolation and genetic analysis of circulating tumor DNA in patient plasma.
Kawaguchi T; Holland WS; Gumerlock PH
Methods Mol Med; 2003; 85():257-62. PubMed ID: 12710213
[No Abstract] [Full Text] [Related]
8. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma.
Tsao MS; Liu N; Nicklee T; Shepherd F; Viallet J
Clin Cancer Res; 1997 Oct; 3(10):1807-14. PubMed ID: 9815567
[TBL] [Abstract][Full Text] [Related]
9. Cancer: Closing the door on KRAS-mutant lung cancer.
Cully M
Nat Rev Drug Discov; 2016 Nov; 15(11):747. PubMed ID: 27807355
[No Abstract] [Full Text] [Related]
10. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
11. Kras and Hras--what is the difference?
Berns A
Nat Genet; 2008 Oct; 40(10):1149-50. PubMed ID: 18818716
[No Abstract] [Full Text] [Related]
12. Context-dependent cancer risk.
Hunter KW
Nat Genet; 2006 Aug; 38(8):864-5. PubMed ID: 16874325
[No Abstract] [Full Text] [Related]
13. [CDK4, a specific target in the treatment of lung adenocarcinomas mutated for KRAS].
Dubus P
Med Sci (Paris); 2010 Dec; 26(12):1023-5. PubMed ID: 21187034
[No Abstract] [Full Text] [Related]
14. The interplay between ras oncogenes and tumor suppressor genes in experimental carcinogenesis.
Balmain A; Brown K; Bremner R
Immunol Ser; 1990; 51():75-88. PubMed ID: 2128916
[No Abstract] [Full Text] [Related]
15. Human lung cancers growing on extracellular matrix: expression of oncogenes and growth factors.
Pavelic K; Antonic M; Pavelic L; Pavelic J; Pavelic Z; Spaventi S
Anticancer Res; 1992; 12(6B):2191-6. PubMed ID: 1363516
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of carcinogenesis: the role of oncogenes, transcriptional enhancers and growth factors.
Spandidos DA
Anticancer Res; 1985; 5(5):485-98. PubMed ID: 3904595
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
18. Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.
Mukhopadhyay T; Tainsky M; Cavender AC; Roth JA
Cancer Res; 1991 Mar; 51(6):1744-8. PubMed ID: 1998965
[TBL] [Abstract][Full Text] [Related]
19. Integrin signaling to NF-kappa B in monocytic leukemia cells is blocked by activated oncogenes.
Rosales C; Juliano R
Cancer Res; 1996 May; 56(10):2302-5. PubMed ID: 8625304
[TBL] [Abstract][Full Text] [Related]
20. [A study on P21(ras) in human lung cancer and body fluid of cancer patients].
Lin X; Shu X; Sun Z; Zhao J; Sun Z
Hua Xi Yi Ke Da Xue Xue Bao; 1993 Sep; 24(3):233-6. PubMed ID: 8288186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
